Bristol-Myers Squibb Company Ce (CELG-RI) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate Bristol-Myers Squibb Company Ce's investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
11.63
Strong
WeakModerateStrong
P/B Ratio
7.63
Weak
WeakModerateStrong
Earnings Yield
8.60%
Strong
WeakModerateStrong
Profitability Health
2018Return on Equity
65.67%
Strong
WeakModerateStrong
Operating Margin
33.97%
Strong
WeakModerateStrong
Net Profit Margin
26.48%
Strong
WeakModerateStrong
Growth Indicators
2018Revenue Growth
17.52%
Strong
WeakModerateStrong
Net Income Growth
37.62%
Strong
WeakModerateStrong
EPS Growth
46.15%
Strong
WeakModerateStrong
Efficiency & Liquidity
2018Current Ratio
2.23
Strong
WeakModerateStrong
Quick Ratio
2.12
Strong
WeakModerateStrong
Asset Turnover
0.43x
Weak
WeakModerateStrong
Inventory Turnover
1.28x
Weak
WeakModerateStrong
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
10.29%
Strong
WeakModerateStrong
EV / Free Cash Flow
13.03x
Strong
WeakModerateStrong
Net Debt / EBITDA
2.58x
Weak
WeakModerateStrong
Interest Burden (EBT / EBIT)
0.931
Moderate
WeakModerateStrong
Return on Invested Capital
13.62%
Weak
WeakModerateStrong
Cash Conversion Cycle
74.22 days
Weak
WeakModerateStrong
Fortress screener guardrails
1/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for CELG-RI.
View Financial Statements